|
Catalogusnummer
|
Internationale chemische identificatie
|
EG-nr.
|
CAS-nr.
|
Indeling
|
Etikettering
|
Specifieke concentratiegrenzen, M-factoren en ATE's
|
Opmerkingen
|
|
Gevarenklasse en categorie
|
Gevarenaanduiding
|
Pictogram, signaalwoord
|
Gevarenaanduiding
|
Aanvullende gevarenaanduiding
|
|
„047-003-00-3
|
zilverzinkzeoliet (zeoliet, type LTA, oppervlakte gewijzigd met zilver- en zinkionen)
[Deze rubriek betreft zeoliet van het type LTA (Linde-type A) waarvan de oppervlakte is gewijzigd met zowel zilver- als zinkionen met de gehalten Ag+ 0,5 % — 6 %, Zn2 + 5 % — 16 %, en eventueel met fosfor, NH4+, mg2+ en/of Ca2+, telkens < 3 %]
|
—
|
130328-20-0
|
Repr. 2
Skin Irrit. 2
Eye Dam. 1
Aquatic Acute 1
Aquatic Chronic 1
|
H361d
H315
H318
H400
H410
|
GHS08
GHS05
GHS09
Dgr
|
H361d
H315
H318
H410
|
|
M = 100
M = 100”
|
|
|
„048-012-00-5
|
cadmiumcarbonaat
|
208-168-9
|
513-78-0
|
Carc. 1B
Muta. 1B
Acute Tox. 4 *
Acute Tox. 4 *
Acute Tox. 4 *
STOT RE 1
Aquatic Acute 1
Aquatic Chronic 1
|
H350
H340
H332
H312
H302
H372 (nier, bot)
H400
H410
|
GHS08
GHS07
GHS09
Dgr
|
H350
H340
H332
H312
H302
H372 (nier, bot)
H410
|
|
|
A1”
|
|
„048-013-00-0
|
cadmiumhydroxide; cadmiumdihydroxide
|
244-168-5
|
21041-95-2
|
Carc. 1B
Muta. 1B
Acute Tox. 4 *
Acute Tox. 4 *
Acute Tox. 4 *
STOT RE 1
Aquatic Acute 1
Aquatic Chronic 1
|
H350
H340
H332
H312
H302
H372 (nier, bot)
H400
H410
|
GHS08
GHS07
GHS09
Dgr
|
H350
H340
H332
H312
H302
H372 (nier, bot)
H410
|
|
|
A1”
|
|
„048-014-00-6
|
cadmiumnitraat;
cadmiumdinitraat
|
233-710-6
|
10325-94-7
|
Carc. 1B
Muta. 1B
Acute Tox. 4 *
Acute Tox. 4 *
Acute Tox. 4 *
STOT RE 1
Aquatic Acute 1
Aquatic Chronic 1
|
H350
H340
H332
H312
H302
H372 (nier, bot)
H400
H410
|
GHS08
GHS07
GHS09
Dgr
|
H350
H340
H332
H312
H302
H372 (nier, bot)
H410
|
|
Carc. 1B; H350:
C ≥ 0,01 %
|
A1”
|
|
„050-030-00-3
|
dibutyltindilauraat; dibutyl[bis(dodecanoyloxy)]stannaan
|
201-039-8
|
77-58-7
|
Muta. 2
Repr. 1B
STOT RE 1
|
H341
H360FD
H372 (immuunsysteem)
|
GHS08
Dgr
|
H341
H360FD
H372 (immuunsysteem)”
|
|
|
|
|
„603-235-00-2
|
linalool; 3,7-dimethyl-1,6-octadieen-3-ol; dl-linalool; [1]
coriandrol; (S)-3,7-dimethyl-1,6-octadieen-3-ol; d-linalool; [2]
licareol; (R)-3,7-dimethyl-1,6-octadieen-3-ol; l-linalool [3]
|
201-134-4 [1]
204-810-7 [2]
204-811-2 [3]
|
78-70-6 [1]
126-90-9 [2]
126-91-0 [3]
|
Skin Sens. 1B
|
H317
|
GHS07
Wng
|
H317”
|
|
|
|
|
„604-093-00-4
|
chlorofeen;
2-benzyl-4-chloorfenol
|
204-385-8
|
120-32-1
|
Carc. 2
Repr. 2
Acute Tox. 4
Skin Irrit. 2
Skin Sens. 1
Eye Dam. 1
STOT RE 2
Aquatic Acute 1
Aquatic Chronic 1
|
H351
H361f
H332
H315
H317
H318
H373 (nier)
H400
H410
|
GHS08
GHS05
GHS07
GHS09
Dgr
|
H351
H361f
H332
H315
H317
H318
H373 (nier)
H410
|
|
M = 1
M = 100”
|
|
|
„606-150-00-9
|
clethodim (ISO); (5RS)-2-{(1EZ)-1-[(2E)-3-chloorallyloxyimino]propyl}-5-[(2RS)-2-(ethylthio)propyl]-3-hydroxycyclohex-2-en-1-on
|
—
|
99129-21-2
|
Acute Tox. 4
Skin Sens. 1
Aquatic Chronic 3
|
H302
H317
H412
|
GHS07
Wng
|
H302
H317
H412
|
EUH066”
|
|
|
|
„606-151-00-4
|
antrachinon
|
201-549-0
|
84-65-1
|
Carc. 1B
|
H350
|
GHS08
Dgr
|
H350”
|
|
|
|
|
„607-720-00-X
|
nonadecafluordecaanzuur; [1]
ammoniumnonadecafluordecanoaat; [2]
natriumnonadecafluordecanoaat [3]
|
206-400-3 [1] 221-470-5 [2]
[3]
|
335-76-2 [1] 3108-42-7 [2]
3830-45-3 [3]
|
Carc. 2
Repr. 1B
Lact.
|
H351
H360Df
H362
|
GHS08
Dgr
|
H351
H360Df
H362”
|
|
|
|
|
„607-721-00-5
|
N,N′-methyleendimorfoline;
N,N′-methyleenbismorfoline;
[uit N,N′-methyleenbismorfoline vrijkomende formaldehyde];
[MBM]
|
227-062-3
|
5625-90-1
|
Carc. 1B
Muta. 2
Acute Tox. 4
Acute Tox. 4
Acute Tox. 4
STOT RE 2
Skin Corr. 1B
Skin Sens. 1
Eye Dam. 1
|
H350
H341
H332
H312
H302
H373 (spijsverteringskanaal, luchtwegen)
H314
H317
H318
|
GHS08
GHS07
GHS05
Dgr
|
H350
H341
H332
H312
H302
H373 (spijsverteringskanaal, luchtwegen)
H314
H317
|
EUH071
|
|
8
9”
|
|
„607-722-00-0
|
2,3,5,6-tetrafluor-4-(methoxymethyl)benzyl-(Z)-(1R,3R)-3-(2-cyaanprop-1-enyl)-2,2-dimethylcyclopropaan-carboxylaat;
epsilon-momfluorothrine
|
—
|
1065124-65-3
|
Acute Tox. 4
STOT SE 2
Aquatic Acute 1
Aquatic Chronic 1
|
H302
H371 (zenuwstelsel)
H400
H410
|
GHS07
GHS08
GHS09
Wng
|
H302
H371 (zenuwstelsel)
H410
|
|
M = 100
M = 100”
|
|
|
„607-723-00-6
|
tefluthrin (ISO);
2,3,5,6-tetrafluor-4-methylbenzyl-(1RS,3RS)-3-[(Z)-2-chloor-3,3,3-trifluorprop-1-enyl]-2,2-dimethylcyclopropaan-carboxylaat
|
—
|
79538-32-2
|
Acute Tox. 1
Acute Tox. 2
Acute Tox. 2
Aquatic Acute 1
Aquatic Chronic 1
|
H330
H310
H300
H400
H410
|
GHS06
GHS09
Dgr
|
H330
H310
H300
H410
|
|
M = 10 000
M = 10 000 ”
|
|
|
„612-290-00-1
|
reactieproducten van paraformaldehyde en 2-hydroxypropylamine (verhouding 3:2);
[uit 3,3′-methyleenbis[5-methyloxazolidine] vrijkomende formaldehyde;
uit oxazolidine vrijkomende formaldehyde];
[MBO]
|
—
|
—
|
Carc. 1B
Muta. 2
Acute Tox. 4
Acute Tox. 3
Acute Tox. 4
STOT RE 2
Skin Corr. 1B
Eye Dam. 1
Skin Sens. 1A
Aquatic Chronic 2
|
H350
H341
H332
H311
H302
H373 (spijsverteringskanaal, luchtwegen)
H314
H318
H317
H411
|
GHS08
GHS06
GHS05
GHS09
Dgr
|
H350
H341
H332
H311
H302
H373 (spijsverteringskanaal, luchtwegen)
H314
H317
H411
|
EUH071
|
|
8
9”
|
|
„612-291-00-7
|
reactieproducten van paraformaldehyde met 2-hydroxypropylamine (verhouding 1:1);
[uit α,α,α-trimethyl-1,3,5-triazine-1,3,5(2H,4H,6H)-triethanol vrijkomende formaldehyde];
[HPT]
|
—
|
—
|
Carc. 1B
Muta. 2
Acute Tox. 4
Acute Tox. 4
STOT RE 2
Skin Corr. 1C
Eye Dam. 1
Skin Sens. 1A
Aquatic Chronic 2
|
H350
H341
H332
H302
H373 (spijsverteringskanaal, luchtwegen)
H314
H318
H317
H411
|
GHS08
GHS07
GHS05
GHS09
Dgr
|
H350
H341
H332
H302
H373 (spijsverteringskanaal, luchtwegen)
H314
H317
H411
|
EUH071
|
|
8
9”
|
|
„612-292-00-2
|
methylhydrazine
|
200-471-4
|
60-34-4
|
Carc. 1B
|
H350
|
GHS08
Dgr
|
H350”
|
|
|
|
|
„613-321-00-1
|
(RS)-4-[1-(2,3-dimethylfenyl)ethyl]-1H-imidazool;
medetomidine
|
—
|
86347-14-0
|
Acute Tox. 2
Acute Tox. 2
STOT SE 3
STOT SE 1
STOT RE 1
Aquatic Acute 1
Aquatic Chronic 1
|
H330
H300
H336
H370 (oog)
H372
H400
H410
|
GHS06
GHS08
GHS09
Dgr
|
H330
H300
H336
H370 (oog)
H372
H410
|
|
M = 1
M = 100”
|
|
|
„613-322-00-7
|
triadimenol (ISO); (1RS,2RS;1RS,2SR)-1-(4-chloorfenoxy)-3,3-dimethyl-1-(1H-1,2,4-triazool-1-yl)butaan-2-ol;
α-tert-butyl-β-(4-chloorfenoxy)-1H-1,2,4-triazool-1-ethanol
|
259-537-6
|
55219-65-3
|
Repr. 1B
Lact.
Acute Tox. 4
Aquatic Chronic 2
|
H360
H362
H302
H411
|
GHS08
GHS07
GHS09
Dgr
|
H360
H362
H302
H411”
|
|
|
|
|
„613-323-00-2
|
terbutylazine (ISO);
N-tert-butyl-6-chloor-N′-ethyl-1,3,5-triazine-2,4-diamine
|
227-637-9
|
5915-41-3
|
Acute Tox. 4
STOT RE 2
Aquatic Acute 1
Aquatic Chronic 1
|
H302
H373
H400
H410
|
GHS07
GHS08
GHS09
Wng
|
H302
H373
H410
|
|
M = 10
M = 10”
|
|
|
„613-324-00-8
|
chinoline-8-ol;
8-hydroxychinoline
|
205-711-1
|
148-24-3
|
Repr. 1B
Acute Tox. 3
Eye Dam. 1
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
|
H360D
H301
H318
H317
H400
H410
|
GHS08
GHS06
GHS05
GHS09
Dgr
|
H360D
H301
H318
H317
H410
|
|
M = 1
M = 1”
|
|
|
„613-325-00-3
|
thiacloprid (ISO);
(Z)-3-(6-chloor-3-pyridylmethyl)-1,3-thiazolidine-2-ylideencyaanamide;
{(2Z)-3-[(6-chloorpyridine-3-yl)methyl]-1,3-thiazolidine-2-ylideen}cyaanamide
|
—
|
111988-49-9
|
Carc. 2
Repr. 1B
Acute Tox. 4
Acute Tox. 3
STOT SE 3
Aquatic Acute 1
Aquatic Chronic 1
|
H351
H360FD
H332
H301
H336
H400
H410
|
GHS08 GHS06
GHS09
Dgr
|
H351
H360FD
H332
H301
H336
H410
|
|
M = 100
M = 100”
|
|
|
„616-221-00-6
|
hexaflumuron (ISO);
1-(3,5-dichloor-4-(1,1,2,2-tetrafluorethoxy)fenyl)-3-(2,6-difluorbenzoyl)ureum
|
401-400-1
|
86479-06-3
|
Aquatic Acute 1
Aquatic Chronic 1
|
H400
H410
|
GHS09
Wng
|
H410
|
|
M = 1 000
M = 10 000 ”
|
|
|
„616-222-00-1
|
penthiopyrad (ISO);
(RS)-N-[2-(1,3-dimethylbutyl)-3-thienyl]-1-methyl-3-(trifluormethyl)pyrazool-4-carboxamide
|
—
|
183675-82-3
|
Aquatic Acute 1
Aquatic Chronic 1
|
H400
H410
|
GHS09
Wng
|
H410
|
|
M = 1
M = 1”
|
|
|
„616-223-00-7
|
carbetamide (ISO);
(R)-1-(ethylcarbamoyl)ethyl-carbanilaat; (2R)-1-(ethylamino)-1-oxopropaan-2-yl-fenylcarbamaat
|
240-286-6
|
16118-49-3
|
Carc. 2
Repr. 1B
Acute Tox. 4
Aquatic Chronic 2
|
H351
H360D
H302
H411
|
GHS08
GHS07
GHS09
Dgr
|
H351
H360D
H302
H411”
|
|
|
|